Tag Archives: MiMedx Group

A Director at MiMedx Group is Exercising Options

Today it was reported that a Director at MiMedx Group (MDXG – Research Report), Terry Dewberry, exercised options to buy 50,000 MDXG shares at $0.70 a share, for a total transaction value of $35K. Following this transaction Terry Dewberry’s holding

MiMedx Group Gets a Hold Rating from Needham

Needham analyst Michael Matson maintained a Hold rating on MiMedx Group (NASDAQ: MDXG) today. The company’s shares opened today at $7.24, close to its 52-week low of $6.05. Matson noted: “This morning (3/15/18), MDXG issued a press release announcing: 1)

The President & COO of MiMedx Group is Exercising Options

Today, the President & COO of MiMedx Group, William Charles Taylor, exercised options of MiMedx Group for $33K. Following this transaction William Charles Taylor’s holding in the company was increased by 3.72% to a total of $3.95 million. Based on

Piper Jaffray Believes MiMedx Group (NASDAQ: MDXG) Won’t Stop Here

Piper Jaffray analyst Matthew O’Brien reiterated a Buy rating on MiMedx Group (NASDAQ: MDXG) on August 18 and set a price target of $18. The company’s shares closed on Friday at $16.52, close to its 52-week high of $17.36. According

Analysts Offer Insights on Healthcare Companies: MiMedx Group (NASDAQ: MDXG), Amarin (NASDAQ: AMRN) and Cytokinetics Inc (NASDAQ: CYTK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MiMedx Group (NASDAQ: MDXG), Amarin (NASDAQ: AMRN) and Cytokinetics Inc (NASDAQ: CYTK) with bullish sentiments. MiMedx Group (NASDAQ: MDXG) In a report

Needham Believes MiMedx Group (NASDAQ: MDXG) Still Has Room to Grow

In a report released today, Michael Matson from Needham reiterated a Buy rating on MiMedx Group (NASDAQ: MDXG), with a price target of $20. The company’s shares closed last Friday at $15.71, close to its 52-week high of $16.04. Matson